Allogene Therapeutics
ALLO
209 hedge funds and large institutions have $445M invested in Allogene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 80 increasing their positions, 40 reducing their positions, and 12 closing their positions.
325% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 12
108% more call options, than puts
Call options by funds: $776K | Put options by funds: $373K
100% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 40
100% more capital invested
Capital invested by funds: $223M → $445M (+$222M)
22% more funds holding
Funds holding: 172 → 209 (+37)
3.18% more ownership
Funds ownership: 72.38% → 75.56% (+3.2%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$11.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$6.34M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
+$5.46M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.7M |
| 2 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
-$3.49M |
| 3 |
Jane Street
New York
|
-$3.32M |
| 4 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$3.03M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.82M |
ALLO Hedge Fund Activity: Q1 2026 in Review
209 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2026, worth a combined $445M — up 100% from $223M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ALLO positions and 12 closed out — a net gain of 39 holders — while 80 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $11.8M. The largest seller was Citadel Advisors, cutting an estimated $10.7M.
- 209 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2026, up from 172 in Q4 2025.
- Funds reported $445M of Allogene Therapeutics stock for Q1 2026, up 100% quarter-over-quarter.
- 51 funds opened new Allogene Therapeutics positions in Q1 2026 and 12 closed out, a net change of +39 holders.
- The largest Allogene Therapeutics buyer in Q1 2026 was State Street, an estimated $11.8M added.
- The largest Allogene Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2026.